Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact^® Survey 2018

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Li J, Siegel DA, King JB. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004–2014. Ann Epidemiol. 2018;28:328–330. doi:10.1016/j.annepidem.2018.03.00129678312
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Konety BR, Crook J, et al. Landmarks in prostate cancer. Nat Rev Urol. 2018;15:627–642. doi:10.1038/s41585-018-0060-730065357
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER*Explorer; 2020. Available from: https://seer.cancer.gov/explorer/. Accessed August 16, 2020.
   Google Scholar
• Facchini G, Perri F, Misso G, et al. Optimal management of prostate cancer based on its natural clinical history. Curr Cancer Drug Targets. 2018;18:457–467. doi:10.2174/156800961766617020909310128183253
   PubMed Web of Science ®Google Scholar
• Imber BS, Varghese M, Ehdaie B, et al. Financial toxicity associated with treatment of localized prostate cancer. Nat Rev Urol. 2020;17:28–40. doi:10.1038/s41585-019-0258-331792431
   PubMed Web of Science ®Google Scholar
• Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–690. doi:10.1016/j.juro.2017.11.09529203269
   PubMed Web of Science ®Google Scholar
• Wilcox SW, Aherne NJ, Benjamin LC, et al. Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer. Onco Targets Ther. 2014;7:1519–1523. doi:10.2147/OTT.S6523825210465
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Rumble RB, Chen RC, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018;36:3251–3258. doi:10.1200/JCO.18.0060630183466
   PubMed Web of Science ®Google Scholar
• Artibani W, Porcaro AB, De Marco V, et al. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100:251–262. doi:10.1159/00048143829161715
   PubMed Web of Science ®Google Scholar
• Gul A, Garcia JA, Barata PC. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide. Cancer Manag Res. 2019;11:7253–7262. doi:10.2147/CMAR.S16570631534371
   PubMed Web of Science ®Google Scholar
• El-Amm J, Aragon-Ching JB. The current landscape of treatment in non-metastatic castration-resistant prostate cancer. Clin Med Insights Oncol. 2019;13:1179554919833927. doi:10.1177/117955491983392730872920
   PubMed Web of Science ®Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402–1418. doi:10.1200/JCO.2015.64.270226903579
   PubMed Web of Science ®Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505. doi:10.6004/jnccn.2019.002331085757
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14:19–30. doi:10.6004/jnccn.2016.000426733552
   PubMed Web of Science ®Google Scholar
• Loppenberg B, Sood A, Dalela D, et al. Variation in locoregional prostate cancer care and treatment trends at commission on cancer designated facilities: a national cancer data base analysis 2004 to 2013. Clin Genitourin Cancer. 2017;15:e955–e968. doi:10.1016/j.clgc.2017.04.01428558991
   PubMed Web of Science ®Google Scholar
• Vernooij RWM, van Oort I, de Reijke TM, et al. Nationwide treatment patterns and survival of older patients with prostate cancer. J Geriatr Oncol. 2019;10:252–258. doi:10.1016/j.jgo.2018.06.01030853064
   PubMed Web of Science ®Google Scholar
• EAU Guidelines Office, Arnhem, The Netherlands. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed January 9, 2020.
   Google Scholar
• Morash C, Tey R, Agbassi C, et al. Active surveillance for the management of localized prostate cancer: guideline recommendations. Can Urol Assoc J. 2015;9:171–178. doi:10.5489/cuaj.280626225165
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629. doi:10.1016/j.eururo.2016.08.00327568654
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309:2587–2595. doi:10.1001/jama.2013.688223800935
   PubMed Web of Science ®Google Scholar
• Kwak YK, Lee SW, Kay CS, et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017;12:e0183339. doi:10.1371/journal.pone.018333928846718
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439. doi:10.1001/jama.294.4.43316046649
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Mahadevan A, Reddy CA, et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68:593–598. doi:10.1016/j.urology.2006.03.07516979731
   PubMed Web of Science ®Google Scholar
• Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol. 2004;172:910–914. doi:10.1097/01.ju.0000134888.22332.bb15310996
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–351. doi:10.1056/NEJMoa170290028578639
   PubMed Web of Science ®Google Scholar
• Shah R, Botteman M, Waldeck R. Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan. Future Oncol. 2019;15:4069–4081. doi:10.2217/fon-2019-056331687847
   PubMed Web of Science ®Google Scholar